
    
      An open-ended prospective non-randomized study involving volunteers over the age of 60.

      The study will include 110 volunteers. who will receive the test drug according to the
      prime-boost scheme: the introduction of component 1 will be carried out on the 1st day, and
      component 2 - on the 21st day of the study. Outpatient monitoring will be performed during 4
      visits: on the 7th, 14th, 28th, and 42nd days after the vaccine administration Also two
      visits will be performed in the phone contact mode for 90 and 180 days
    
  